menu
    • menu
    [{"orgOrder":0,"company":"Supriya Lifescience","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Bucillamine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Supriya Lifescience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Supriya Lifescience \/ Revive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Supriya Lifescience \/ Revive Therapeutics"},{"orgOrder":0,"company":"Supriya Lifescience","sponsor":"Kalinga Institute of Technology","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"INDIA","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Protein-based Crosslinked Hydrogel","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Supriya Lifescience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Supriya Lifescience \/ Kalinga Institute of Technology","highestDevelopmentStatusID":"4","companyTruncated":"Supriya Lifescience \/ Kalinga Institute of Technology"},{"orgOrder":0,"company":"Supriya Lifescience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Supriya Lifescience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Supriya Lifescience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Supriya Lifescience \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Supriya Lifescience

    Menu

    Supriya Lifescience

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Supriya Lifescience

                            India
                            CPhI Japan
                            Booth #5Q-2
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSupriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

                            Lead Product(s) : Esketamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Supriya Lifescience Expands Global Footprint with Esketamine Hydrochloride Approval

                            Details : Esketamine HCl is a non-selective, non-competitive NMDA receptor antagonist, approved for treating mental illness.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 09, 2024

                            Lead Product(s) : Esketamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Supriya

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Supriya Lifescience

                            India
                            CPhI Japan
                            Booth #5Q-2
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSupriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

                            Lead Product(s) : Protein-based Crosslinked Hydrogel

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : Kalinga Institute of Technology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Supriya Lifescience Signs Agreement with KIT for Further Development of Wound Healing Gel

                            Details : Through the agreement, Supriya Lifescience will focus on the advancement of GelHeal, a protein-based crosslinked Hydrogel, gel-based cream, which is being evaluated for the treatment of deep wounds.

                            Product Name : GelHeal

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 06, 2023

                            Lead Product(s) : Protein-based Crosslinked Hydrogel

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : Kalinga Institute of Technology

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Supriya

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Supriya Lifescience

                            India
                            CPhI Japan
                            Booth #5Q-2
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSupriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

                            Lead Product(s) : Bucillamine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Revive Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India

                            Details : Revive Therapeutics and Indian specialty pharma firm, Supriya Lifescience have signed an MOU to pursue the manufacturing of the API, conduct clinical registration, and commercialize Bucillamine in the treatment of mild-to-moderate COVID-19 in India.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 08, 2021

                            Lead Product(s) : Bucillamine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Revive Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Supriya

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth